Every material Form 8-K Autolus Therapeutics plc has filed with the SEC since August 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Autolus reported second-quarter 2026 AUCATZYL net product revenue of $45.7 million, up from $20.9 million a year earlier, and raised its full-year 2026 AUCATZYL revenue guidance to $140 million to $150 million from $120 million to $135 million. Net loss narrowed to $39.1 million from $47.9 million, and the company said its cash runway now extends into Q2 2028 after a credit facility draw.
Q2 2026 net product revenue was $45.7 million, versus $20.9 million in Q2 2025 and $26.2 million in Q1 2026.
Gross margin was 55% in Q2 2026, up from 6% in Q1 2026 and negative in all 2025 quarters.
Net loss was $39.1 million, or $(0.15) per share, compared with $47.9 million, or $(0.18) per share, a year earlier.
Cash, cash equivalents and marketable securities were $201.6 million at June 30, 2026, versus $229.4 million at March 31, 2026.
Autolus raised its full-year 2026 AUCATZYL net product revenue guidance to $140 million to $150 million, up from $120 million to $135 million, and reported preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million. The company also entered a credit facility of up to $250 million with Perceptive Advisors, with $75 million funded at close, and expects its cash to fund operations into the second quarter of 2028.
Full-year 2026 AUCATZYL net product revenue guidance raised to $140 million to $150 million, from $120 million to $135 million
Preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million, up approximately 70% from Q1 2026 and more than 100% from Q2 2025
Gross margin of approximately 35% year-to-date in 2026, compared with approximately negative 20% in the second half of 2025
Five-year, interest-only credit facility with Perceptive of up to $250 million; $75 million issued July 30, 2026, at SOFR (3.50% floor) plus 7.25%, with a warrant for up to 3.5 million ADSs at $1.9314 per ADS
Autolus Therapeutics signed a Note Purchase Agreement on July 30, 2026, for a senior secured notes facility of up to $250.0 million, with $75.0 million issued at closing. The company also issued Perceptive a warrant for up to 3,500,000 ADSs, which adds potential future share dilution, and agreed to file a resale registration statement within 45 calendar days of closing.
Tranche 1 notes of $75.0 million issued July 30, 2026; up to $175.0 million more available in three tranches
Interest is a margin of 6.75% to 7.25% plus the greater of one-month term SOFR and 3.50%; maturity July 30, 2031
Warrant for up to 3,500,000 ADSs at $1.9314 per ADS, expiring July 30, 2036; notes are secured by substantially all company and subsidiary assets
Financial covenants require minimum liquidity of $12.5 million to $50.0 million and minimum Consolidated Net Revenue
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Autolus Therapeutics plc filing is on SEC EDGAR ↗. 8-K briefs of other companies →